Search Results
151 Results Found for “genetic markers”
How advances in molecular understanding are shaping Parkinson's disease classification, patient stratification, and the future of personalized care Parkinson’s disease has historically been diagnosed and classified primarily according to clinical features. However, advances in genetics, molecular biomarkers, and our ...
Highlights from the European Academy of Neurology (EAN) 2026 Congress included new phase 3 data in ocular myasthenia gravis, emerging migraine treatments, longer-term results in multiple sclerosis, and advances in deep brain stimulation for Parkinson’s disease. The 12th Congress of the ...
Prof. Arcadi Navarro discusses BBRC's largest-ever presence at AAIC, the growing role of biomarkers and personalized risk prediction, and why prevention is becoming the future of Alzheimer's disease research. Introduction We spoke with Prof. Arcadi Navarro, Professor of Genetics and ...
Dr Klaus Dugi discusses the first-in-human data for VNA-318, the rationale for targeting cellular energy metabolism in Alzheimer's disease, and how improving mitochondrial function could offer both symptomatic and disease-modifying benefits. We spoke with Klaus Dugi, Chief Executive Officer of ...
Meet the future leaders transforming neurology The touchNEUROLOGY Future Leaders 2026 programme recognizes outstanding early- and mid-career clinicians, researchers and scientists who are shaping the future of neurology. Nominated by peers across the global neurology community, these innovators are leading advances ...
We are delighted to announce Dr Brandon Holmes as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of neurodegenerative disease. We spoke with Dr Brandon Holmes (Memory and Aging Center and Weill Institute ...
We are delighted to announce Dr Erdi Sahin as a touchNEUROLOGY Future Leader 2026, selected by peers as one of the neurologists changing the future of neurodegenerative disease. We spoke with Dr Erdi Sahin, an Assistant Professor in the Department of ...
Kathy Costello, CMSC, and Bonnie Blain, IOMS, join together to discuss four decades of innovation in MS, from MRI and DMTs, to emerging neuroprotective strategies and personalized care. As the Consortium of Multiple Sclerosis Centers (CMSC) celebrates its 40th ...
Dr Micah Luftig discusses the implications for clinical risk stratification and early intervention, and how EBV-targeted strategies may shape future therapeutic approaches Growing evidence has positioned Epstein–Barr virus (EBV) as a central factor in the development of multiple sclerosis (...
The late-breaking science sessions at AAN Annual Meeting 2026, Chicago, IL, USA brought together a wide range of pivotal and practice-shaping data spanning rare disease, neuroimmunology, headache, epilepsy, neurodegeneration and neuromuscular medicine. Several presentations reported positive phase III findings, while others ...
Six key oral presentations from this year’s ADI meeting on diagnosis, therapies and innovation in care Conference coverage | Held from 14–16 April, the 37th Global Conference of Alzheimer’s Disease International (ADI), Lyon, France, brought together global expertise and lived ...
The Alzheimer’s and Parkinson’s Diseases Conference (AD/PD) 2026, held in Copenhagen, Denmark, brought together over 5,800 delegates to discuss advances across neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS) and related disorders. ...
The Bidirectional Nexus of Sleep and Alzheimer’s Disease: Mechanisms and Translational Opportunities
Alzheimer’s disease (AD), the most prevalent cause of dementia, is a progressive neurodegenerative disorder marked by the abnormal accumulation of amyloid-beta (Aβ) plaques and neurofibrillary tau tangles. It currently affects more than 50 million individuals worldwide, with projections reaching over 210 ...
In this year-end review, we are pleased to share personal highlights from members of the touchNEUROLOGY Editorial Board, whose perspectives offer a window into the innovations that have most influenced clinical practice and research over the past 12 months. Their reflections capture not only the momentum of 2025, but also the promise of what lies ahead as the field continues to evolve.
The International League Against Epilepsy (ILAE) is a leading global organisation devoted to epilepsy research, education, advocacy and care. Founded in 1909, it now comprises more than 120 national chapters worldwide and serves as a premier resource for clinicians, scientists and public-health ...
“The Pathways to Cures roadmap was built through global consensus so we can focus on the most impactful research to end MS.” - Bruce Bebo, National MS Society The Pathways to Cures roadmap represents one of the most coordinated global ...
It is my pleasure to introduce the 2025 of touchREVIEWS in Neurology, which brings together an exceptional collection of reviews, original research and congress highlights that reflect the continued evolution of neurological science and clinical innovation. This issue opens with Jelle ...
Between 60% and 80% of cases with dementia worldwide are caused by Alzheimer’s disease (AD), making it the most prevalent type of dementia.1 As of 2025, approximately 60 million people worldwide are affected by dementia, and by 2050, projections suggest a rise to nearly 210 ...
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
